Shortening treatment for uncomplicated candidemia
Part of Infections clinical trials.
This trial tests whether a shorter course of the antifungal drug caspofungin (7 days instead of the usual 14) is just as effective for people with uncomplicated candidemia, a bloodstream infection caused by Candida yeast. If you've already had 7 days of caspofungin and your blood is clear of Candida, you might be able to stop treatment sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with candidemia (a Candida infection in the blood) and have already received 7 days of treatment with caspofungin.
- Your blood tests show the Candida infection is gone, and you have no signs of complicated infection (like in the heart, brain, or bones).
- Any central line (like a PICC or port) has been removed or replaced within 48 hours of starting caspofungin.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control during the study.
- You do not have severe liver disease, a weakened immune system (low white blood cell count), or certain other conditions that might make a shorter treatment less safe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a shorter course of antifungal medicine to a longer one for people who have candidemia (a yeast infection in the blood). It looks at whether treating for a shorter time is just as safe and effective, which could mean fewer side effects and a quicker recovery.
This trial compares two lengths of antifungal treatment for a bloodstream yeast infection that has not spread: 7 days versus the standard 14 days. The goal is to see if a shorter course works just as well with fewer side effects.
This trial compares shorter vs longer treatment for children with an uncomplicated yeast (Candida) bloodstream infection once blood cultures are clear. It may help reduce medicine exposure while keeping the infection under control.
This Phase 3 trial tests fosmanogepix to treat adults with candidemia (Candida in the bloodstream) and/or invasive candidiasis (a deep Candida infection). It looks at whether the medicine is effective and safe, and whether it helps the infection improve when doctors also manage the infection source.
This study looks at patients in the intensive care unit who have a new infection with Candida (a type of fungus) despite taking strong antibiotics. It aims to better understand and diagnose these serious infections.
This study tests whether a short course of antifungal medicines changes the natural bacteria in your gut. It is a small early study, so the main goal is to see if the drug has an effect and if it's safe, which could one day help treat gut-related conditions.
Hear when a new Candidemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.